Kolterman O G
Amylin Pharmaceuticals Inc., San Diego, CA 92121, USA.
Diabet Med. 1997 Jun;14 Suppl 2:S35-8. doi: 10.1002/(sici)1096-9136(199706)14:2+<s35::aid-dia402>3.3.co;2-#.
Clinical studies with the human amylin analogue, pramlintide, suggest that it may help to improve glycaemic control in patients with diabetes mellitus using insulin. This has been demonstrated by reductions in postprandial glycaemic excursion, 24-h glucose profile and serum fructosamine concentrations following administration of pramlintide for periods of up to 28 days in patients with Type 1 diabetes. Additionally, preliminary studies with pramlintide in patients with Type 2 diabetes using insulin have indicated its ability to reduce postprandial hyperglycaemia in this population. Thus, this data set suggests a potential role for pramlintide as a partner to insulin for the optimization of glycaemic control in patients with diabetes using insulin.
对人胰淀素类似物普兰林肽的临床研究表明，它可能有助于改善使用胰岛素的糖尿病患者的血糖控制。在1型糖尿病患者中，给予普兰林肽长达28天，餐后血糖波动、24小时血糖曲线和血清果糖胺浓度降低，证明了这一点。此外，对使用胰岛素的2型糖尿病患者进行的普兰林肽初步研究表明，它有能力降低该人群的餐后高血糖。因此，该数据集表明普兰林肽作为胰岛素的辅助药物，在优化使用胰岛素的糖尿病患者血糖控制方面具有潜在作用。
